Companion Diagnostics: A Business Area Fraught With Challenges Ahead
This article was originally published in The Pink Sheet Daily
Executive Summary
The challenges of developing and utilizing companion diagnostics were on the minds of attendees at the Cancer Progress meeting in New York.
You may also be interested in...
FDA Plays Nicely: Fibrocell Laviv Review Drew From Three Centers
Fibrocell’s autologous cell therapy Laviv was reviewed by CBER with significant help from CDER and CDRH, providing a model of how FDA can handle high-tech products that cross traditional boundaries.
Express Scripts Reports Specialty Drug Spending Steadily Rising, And Pipelines Show More To Come
Not only are specialty drugs “the fastest-growing segment of drug spend,” but the pharmacy benefits manager Express Scripts predicts that specialty drug spend will account for 40% of U.S. drug expenditures by 2014.
Express Scripts Reports Specialty Drug Spending Steadily Rising, And Pipelines Show More To Come
Not only are specialty drugs “the fastest-growing segment of drug spend,” but the pharmacy benefits manager Express Scripts predicts that specialty drug spend will account for 40% of U.S. drug expenditures by 2014.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: